Skip to main content
SpringerLink
Log in

Summary of Published Treatment Guidelines

  • Chapter
  • First Online:
Advances in Psoriasis

  • 659 Accesses

Abstract

Psoriasis is a chronic, remitting disease with no definitive cure. Treatment can be challenging with an array of therapeutic modalities from which to choose. To address this challenge, organizations across the globe have produced evidence-based treatment guidelines compiled by expert panels to aid clinicians with decision-making. In this chapter, we consolidate this information to allow the clinician to make evidence-based decisions using multiple societies’ guidelines at once and highlight important similarities and differences that may affect management. These guidelines vary in scope and depth. Some comprehensively describe available topical, phototherapy, and systemics (non-biologics and biologics) with strong recommendations clearly highlighted, while other guideline focus on systemic treatments without definitive recommendations in some cases. Limitations of the guidelines include lack of recommendations for newer biologics and, in some cases, many years without update leading to recommendations based on older research. Psoriasis treatment must be individualized to patients’ needs and preferences, and guidelines must be updated to offer optimal clinical utility; given the rapidity with which the psoriasis treatment landscape is evolving, this is a tall order.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):18–23.

    Google Scholar 

  2. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.

    Article  PubMed  Google Scholar 

  3. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49(5):897–9.

    Article  PubMed  Google Scholar 

  4. Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8.

    Article  PubMed  Google Scholar 

  5. Psoriasis Treatments—National Psoriasis Foundation. https://www.psoriasis.org/about-psoriasis/treatments. Accessed Feb 5 2019.

  6. Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285–94.

    Article  PubMed  Google Scholar 

  7. Belinchón I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–67.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.

    Article  PubMed  Google Scholar 

  9. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–32.

    PubMed  PubMed Central  Google Scholar 

  10. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–34.

    Article  PubMed  Google Scholar 

  11. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135(12):1490–3.

    Article  CAS  PubMed  Google Scholar 

  12. Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol. 2000;25(2):107–10.

    Article  CAS  PubMed  Google Scholar 

  13. Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension. Drug Saf. 1999;20(5):437–49.

    Article  CAS  PubMed  Google Scholar 

  14. Ormerod AD, Campalani E, Goodfield MJD. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2015;90(1):9–20.

    Google Scholar 

  15. Methotrexate. https://livertox.nih.gov/Methotrexate.htm. Accessed Feb 5 2019.

  16. Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010;86(Suppl 3):5–31.

    PubMed  Google Scholar 

  17. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114–35.

    Article  PubMed  Google Scholar 

  18. Canadian guidelines for the management of plaque psoriasis. http://www.dermatology.ca/psoriasisguidelines. Accessed Feb 5 2019.

  19. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59.

    Article  PubMed  Google Scholar 

  20. Raboobee N, Aboobaker J, Jordaan HF, et al. Guideline on the management of psoriasis in South Africa. S Afr Med J. 2010;100(4 Pt 2):257–82.

    CAS  PubMed  Google Scholar 

  21. Diagnosis and management of psoriasis and psoriatic arthritis in adults: a national clinical guideline. https://www.sign.ac.uk/assets/sign121.pdf. Accessed Feb 5 2019.

  22. Management of psoriasis vulgaris. http://www.moh.gov.my/penerbitan/CPG2017/9004.pdf. Accessed Feb 7 2019.

  23. Psoriasis: assessment and management. https://www.nice.org.uk/guidance/cg153/chapter/1-Guidance#principles-of-care. Accessed Feb 9 2019.

  24. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299(3):111–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Daudén E, Puig L, Ferrándiz C, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatology Venereol. 2016;30:1–18.

    Article  Google Scholar 

  26. Kolios AGA, Yawalkar N, Anliker M, et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology. 2016;232(4):385–406.

    Article  PubMed  Google Scholar 

  27. Berth-Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol. 1992;127(3):266–71.

    Article  CAS  PubMed  Google Scholar 

  28. Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol. 1998;139(6):1005–11.

    Article  CAS  PubMed  Google Scholar 

  29. Mrowietz U, Reich K. Psoriasis: new insights into pathogenesis and treatment. Dtsch Arztebl Int. 2009;106(1–2):11–8.

    PubMed  PubMed Central  Google Scholar 

  30. Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol. 2008;26(5):464–76.

    Article  PubMed  Google Scholar 

  31. Pathirana D, Ormerod A, Saiag P, et al. European S3: guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatology Venereol. 2009;23:1–70.

    Article  Google Scholar 

  32. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95–102.

    Article  CAS  PubMed  Google Scholar 

  33. Su J, Pearce DJ, Feldman SR. The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. J Dermatolog Treat. 2005;16(5–6):324–6.

    Article  PubMed  Google Scholar 

  34. Fleischer AB, Clark AR, Rapp SR, et al. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol. 1997;109(2):170–4.

    Article  PubMed  Google Scholar 

  35. Radack KP, Farhangian ME, Anderson KL, et al. A review of the use of tanning beds as a dermatological treatment. Dermatol Ther (Heidelb). 2015;5(1):37–51.

    Article  Google Scholar 

  36. Turner RJ, Farr PM, Walshaw D. Many patients with psoriasis use sunbeds. BMJ. 1998;317(7155):412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nast A, Gisondi P, Ormerod AD, et al. European S3: guidelines on the systemic treatment of psoriasis vulgaris—Update 2015—Short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatology Venereol. 2015;29(12):2277–94.

    Article  CAS  Google Scholar 

  38. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.

    Article  CAS  PubMed  Google Scholar 

  39. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92(6):2675–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016;175(1):23–44.

    Article  CAS  PubMed  Google Scholar 

  41. Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459–72.

    Article  CAS  PubMed  Google Scholar 

  42. Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update—short version part 1—systemic treatment. J Dtsch Dermatol Ges. 2018;16(5):645–69.

    PubMed  Google Scholar 

  43. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14(5):382–8.

    Article  CAS  PubMed  Google Scholar 

  44. Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013;60(1):25–31.

    Article  PubMed  PubMed Central  Google Scholar 

  45. British Association of Dermatologists guidelines for biologic therapy for psoriasis. http://www.bad.org.uk/shared/get-file.ashx?id=5835&itemtype=document. Accessed Feb 10 2019.

  46. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol. 2003;2(4):375–7.

    PubMed  Google Scholar 

  47. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–64.

    Article  PubMed  Google Scholar 

  48. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–36.

    Article  CAS  PubMed  Google Scholar 

  49. Zalevsky J, Secher T, Ezhevsky SA, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007;179(3):1872–83.

    Article  CAS  PubMed  Google Scholar 

  50. Etanercept injection: medlineplus drug information. https://medlineplus.gov/druginfo/meds/a602013.html. Accessed Feb 14 2019.

  51. Siddiqui MAA, Scott LJ. Infliximab. Drugs. 2005;65(15):2179–208.

    Article  PubMed  Google Scholar 

  52. Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Ther Adv Gastroenterol. 2010;3(5):32128.

    Article  CAS  Google Scholar 

  53. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5–21.

    Article  CAS  PubMed  Google Scholar 

  54. Chalmers R, Hollis S, Leonardi-Bee J, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. 2006;25(1):CD001433.

    Google Scholar 

  55. Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21–5.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Cetrolizumab pegol: highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf. Accessed Feb 17 2019.

  57. Kaushik SB, Lebwohl MG, York N. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43–53.

    Article  PubMed  Google Scholar 

  58. Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ. 2007;334(7605):1218–20.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr Drugs. 2015;17(5):373–84.

    Article  CAS  Google Scholar 

  60. Management of psoriasis in low income countries. https://www.ifpma.org/wp-content/uploads/2016/02/1-_DrMahira_Hamdy_El_Sayed_6-5-2014.pdf. Accessed Feb 8 2019.

  61. Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013;92(5):258–63.

    PubMed  Google Scholar 

  62. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59(6):1009–16.

    Article  PubMed  Google Scholar 

  63. Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–7.

    Article  CAS  PubMed  Google Scholar 

  64. Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006;17(5):294–301.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Center for Dermatology Research, Medical Center Boulevard, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Vignesh Ramachandran, Abigail Cline & Steven R. Feldman

  2. Department of Pathology, Medical Center Boulevard, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

  3. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Steven R. Feldman

Authors
  1. Vignesh Ramachandran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abigail Cline
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven R. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ramachandran, V., Cline, A., Feldman, S.R. (2021). Summary of Published Treatment Guidelines. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation